Therapies the necessary protein” (Shannon, S). Proteins then

Therapies for cystic fibrosis can be helped at one of three levels in the cell: DNA, RNA, or protein. DNA is in the nucleus of the cell and contains all the information to create the required proteins however, it cannot move out of nucleus. “Therefore, the instructions contained in DNA are transcribed into RNA, which travels out of the nucleus to create the necessary protein” (Shannon, S). Proteins then are the final stage because they help cells stay alive. So, DNA is used to create RNA and that creates protein. This also means if there is a mutation in one’s DNA, there will also be a mutation in the RNA and in the protein.
In cystic fibrosis there can only be a cure if the mutation is treated in the DNA level. Ivacaftor, which help to restore the function of the protein, does not go in depth to the RNA or DNA. This means that medication like Ivacaftor restores the function of the protein, the cell continues to not work since the mutation is in the DNA and not only the protein.
The cure and goal of cystic fibrosis therapies is to use CRISPR-Cas9 to replace mutated genes in those with the genetic disease. The CRISPR-Cas9 system can target a specific sequence of DNA and cut it out then replace it with the correct gene sequence. The process is already explained in the first two paragraphs of this essay. This is a better solution because the DNA is targeted instead of only the symptoms or the proteins. This could prevent the mutation to be passed onto future generations also. 
The use of the CRISPR-Cas9 system has already begun for example in a study in 2013 published in Cell by Gerald Schwank and colleagues titled “Functional Repair of CFTR by CRISPR-Cas9 in Intestinal Organoids of Cystic Fibrosis Patients”, used CRISPR to correct the CFTR gene in intestinal cells (Shannon, S). In the study, intestinal organoids were taken from two donor patients who were homozygous for the F508del mutation. What the study tested was if it its possible to replace a mutated CFTR gene with the correct gene sequence which would restore the function of the gene. With use of the CRISPR-Cas9, the study was successful in so the function of the CFTR was restored fully, allowing a proper flow of mucus to cross the intestinal cells.
The success of the study shows the potential use of CRISPR-Cas9 in the future for medical purpose like those living with cystic fibrosis. Although it has a bright future, there are still issues to address before this type of technology is used everywhere.